

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Claim 1 (Currently Amended): A method for treating a neoplastic disease or disorder ~~having~~ characterized by cells expressing CD40 in a mammal, comprising:

administering to the mammal ~~a combination consisting essentially of:~~

- a. a CD20 specific binding agent, wherein the CD20 specific binding agent is an antibody that binds CD20; and
- b. a CD40 specific binding [[an]] agent that arrests the growth of or causes deletion of cells expressing CD40, wherein the agent consists of a CD40 specific binding agent that stimulates CD40, wherein the CD40 specific binding agent is a chimeric antibody or a humanized antibody derived from S2C6 (ATCC Accession No. PTA-110);

~~wherein said combination~~ the CD20 specific binding agent and the CD40 specific binding agent in combination inhibits the neoplastic disease or disorder in said mammal.

Claim 2 (Original): The method according to claim 1 wherein the neoplastic disease or disorder is a hematological malignancy.

Claim 3 (Original): The method according to claim 1 wherein the neoplastic disease or disorder is a solid tumor.

Claim 4 (Original): The method according to claim 2 wherein the malignancy is a lymphoma.

Claim 5 (Original): The method according to claim 4 wherein the lymphoma is a non-hodgkins type lymphoma.

Claim 6 (Original): The method according to claim 2 wherein the malignancy is a myeloma.

Claim 7(Original): The method according to claim 6 wherein the myeloma is a multiple myeloma.

Claim 8 (Original): The method according to claim 2 wherein the malignancy is a leukemia.

Claim 9-13 (Cancelled).

Claim 14 (Currently Amended): The method according to claim [[13]] 1 wherein the antibody that binds CD20 is a monoclonal antibody.

Claim 15 (Currently Amended): The method according to claim [[13]] 14 wherein the antibody is a chimeric antibody produced by the transfectoma having ATCC® deposit number 69119.

Claim 16-18 (Cancelled).

Claim 19 (Withdrawn) A pharmaceutical composition for treating a neoplastic disease or disorder characterized by cells expressing CD40, consisting essentially of: (a) an agent that arrests the growth of or causes deletion of cells expressing CD40 wherein the agent consists of a CD40 specific binding agent that stimulates CD40; (b) a CD20 specific binding agent; and (c) a pharmaceutically acceptable carrier.

Claims 20-31 (Cancelled).

Claim 32 (Currently Amended): The method of claim 1, wherein said CD40 specific binding agent and said CD20 specific binding agent are administered simultaneously.

Claim 33 (Currently Amended): The method of claim 1, wherein said CD40 specific binding agent and said CD20 specific binding agent are administered sequentially.

Claim 34-35 (Cancelled).

Claim 36 (Previously Presented): The method of claim 1, wherein the CD20 specific binding agent is a humanized antibody.

Claim 37 (Currently Amended): The method of claim 1, wherein the CD40 specific binding agent is a humanized antibody derived from ~~SGN-14~~ S2C6 (ATCC® Accession No. PTA-110).

Claim 38 (Currently Amended): The method of claim 1, wherein the CD40 specific binding agent is a chimeric antibody derived from ~~SGN-14~~ S2C6 (ATCC® Accession No. PTA-110).

Claim 39 (Currently Amended): The method of claim 1, wherein the CD20 specific binding agent is a humanized antibody derived from ~~rituximab~~ rituximab (ATCC® Accession No. 69119).

Claim 40 (Withdrawn): The method of claim 1, further comprising administering a cytotoxic or chemotherapeutic agent, simultaneously or sequentially with said combination.

Claim 41 (Withdrawn): The method of claim 1, further comprising administering one or more of a maytansine, a calicheamicin, or a trichothene, simultaneously or sequentially with said combination.

Claim 42 (Withdrawn): The method of claim 1, further comprising administering Gemzar™, simultaneously or sequentially with said combination.

Claim 43 (Withdrawn): The method of claim 1, wherein the CD40 specific binding agent, the CD20 specific binding agent, or both, is conjugated to a cytotoxic agent.

Claim 44 (Withdrawn): The method claim 34, wherein the cytotoxic agent comprises a radioactive isotope, a chemotherapeutic agent, or a toxin.

Claim 45 (Withdrawn): The method of claim 1, wherein the CD40 specific binding agent, the CD20 specific binding agent, or both, is conjugated to a prodrug-activating enzyme which converts a prodrug to an active anti-cancer drug.

Claim 46 (Currently Amended): The method of claim [[9]] 37, wherein the humanized antibody is an antibody fragment.

Claim 47 (Currently Amended): The method of claim [[37]] 46, wherein the antibody fragment is a Fab, Fab', ~~F(ab')₂~~ F(ab')₂, Fv, diabody, linear antibody, sFv, or a multispecific antibody formed from antibody fragments.

Claim 48 (Currently Amended): The method of claim [[13]] 1, wherein the antibody that binds to CD20 is an antibody fragment.

Claim 49 (Currently Amended): The method of claim [[39]] 48, wherein the antibody fragment is a Fab, Fab', ~~F(ab')₂~~ F(ab')₂, Fv, diabody, linear antibody, sFv, or a multispecific antibody formed from antibody fragments.

Claim 50 (New): The method of claim 38, wherein the chimeric antibody is an antibody fragment.

Claim 51 (New): The method of claim 50, wherein the antibody fragment is a Fab, Fab', F(ab')₂, Fv, diabody, linear antibody, sFv, or a multispecific antibody formed from antibody fragments.

Claim 52 (New): The method of claim 1, wherein the humanized antibody derived from S2C6 (ATCC Accession No. PTA-110) comprises variable heavy chain complementarity determining residues shown in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3.

Claim 53 (New): The method of claim 1, wherein the humanized antibody derived from S2C6 (ATCC Accession No. PTA-110) comprises variable light chain complementarity determining residues shown in SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6.

Claim 54 (New): The method of claim 52, wherein the humanized antibody derived from S2C6 (ATCC Accession No. PTA-110) further comprises variable light chain complementarity determining residues shown in SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6.

Claim 55 (New): The method of claim 54, wherein the CD20 specific binding agent is a humanized antibody derived from rituximab (ATCC® Accession No. 69119).